Mitobronitol
Names | |
---|---|
Preferred IUPAC name 1,6-Dibromo-1,6-dideoxy-D-mannitol[citation needed] | |
Systematic IUPAC name 1,6-Dibromohexane-2,3,4,5-tetrol[1] | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
ECHA InfoCard | 100.006.979 |
EC Number |
|
KEGG |
|
MeSH | Mitobronitol |
PubChem CID |
|
RTECS number |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C6H12Br2O4 |
Molar mass | 307.966 g·mol−1 |
Appearance | Colourless crystals |
log P | −0.226 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
Acidity (pKa) | 12.609 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
Basicity (pKb) | 1.388 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
Pharmacology | |
L01AX01 (WHO) | |
Related compounds | |
Related compounds | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
Chemical compound
Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is also classified as an alkylating agent.[2]
References
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e